Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
16 June 2020Website:
http://www.royaltypharma.comNext earnings report:
08 August 2024Last dividends:
16 May 2024Next dividends:
N/APrice
after hours | Mon, 01 Jul 2024 21:46:07 GMTAnalysts recommendations
Institutional Ownership
RPRX Latest News
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.5 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”):
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired an interest in Agios Pharmaceuticals' royalty on Servier's vorasidenib for $905 million in upfront cash contingent on U.S. Food and Drug Administration (FDA) approval of vorasidenib.
Royalty Pharma plc (Nasdaq: RPRX) announced today that it will be attending several investor conferences in May.
In addition to examining Wall Street's forecasts for Royalty Pharma (RPRX) in terms of revenue and profit, consider analyzing certain important metrics to better assess the company's performance in the first quarter of 2024.
Royalty Pharma plc (Nasdaq: RPRX) will release its financial results for the first quarter of 2024 on Thursday, May 9, 2024 before the U.S. markets open. A conference call and webcast will be held at 8:00 a.m. Eastern Time on the same day.
While the top- and bottom-line numbers for Royalty Pharma (RPRX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx Conference on November 28, 2023 at 3:00 p.m. ET.
Royalty Pharma PLC (NASDAQ:RPRX ) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants George Grofik - SVP & Head, IR & Communications Pablo Legorreta - Founder, Chairman & CEO Christopher Hite - Vice Chairman & EVP Terrance Coyne - EVP & CFO Marshall Urist - EVP & Head, Research & Investments Conference Call Participants Christopher Schott - JPMorgan Chase & Co. Stephen Scala - TD Cowen Andrew Baum - Citigroup Michael DiFiore - Evercore ISI Chris Shibutani - Goldman Sachs Group Operator Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma Third Quarter 2023 Earnings Conference Call.
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2023 financial results on Wednesday, November 8, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.
- 1(current)
What type of business is Royalty Pharma?
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
What sector is Royalty Pharma in?
Royalty Pharma is in the Healthcare sector
What industry is Royalty Pharma in?
Royalty Pharma is in the Biotechnology industry
What country is Royalty Pharma from?
Royalty Pharma is headquartered in United States
When did Royalty Pharma go public?
Royalty Pharma initial public offering (IPO) was on 16 June 2020
What is Royalty Pharma website?
https://www.royaltypharma.com
Is Royalty Pharma in the S&P 500?
No, Royalty Pharma is not included in the S&P 500 index
Is Royalty Pharma in the NASDAQ 100?
No, Royalty Pharma is not included in the NASDAQ 100 index
Is Royalty Pharma in the Dow Jones?
No, Royalty Pharma is not included in the Dow Jones index
When does Royalty Pharma report earnings?
The next expected earnings date for Royalty Pharma is 08 August 2024